<DOC>
	<DOC>NCT00932698</DOC>
	<brief_summary>This study will determine the safety profile, tolerability, and maximum tolerated dose (MTD) and disease response of IXAZOMIB administered orally in patients with relapsed and/or refractory multiple myeloma.</brief_summary>
	<brief_title>Study of Oral IXAZOMIB in Adult Patients With Relapsed and/or Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<mesh_term>Ixazomib</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<mesh_term>Proteasome Inhibitors</mesh_term>
	<criteria>Each patient must meet all of the following inclusion criteria to be enrolled in the study: Multiple myeloma diagnosed according to the standard criteria. Patients with multiple myeloma who have relapsed following at least 2 lines of therapy. Patients must have measurable disease. ECOG performance status of 0 to 2. Female patients who are post menopausal, surgically sterile, or agree to practice 2 effective methods of contraception or abstain from heterosexual intercourse. Male patients who agree to practice effective barrier contraception or agree to abstain from heterosexual intercourse. Voluntary written consent. Suitable venous access for studyrequired blood sampling. Patients meeting any of the following exclusion criteria are not to be enrolled in the study: Peripheral neuropathy &gt; or equal to Grade 2. Female patients who are lactating or have a positive serum pregnancy test during the screening period. Major surgery within 14 days before the first dose of study drug. Infection requiring systemic antibiotic therapy or other serious infection within 14 days before the first dose of study treatment. Lifethreatening illness unrelated to cancer. Diarrhea &gt; Grade 1, based on the NCI CTCAE categorization. Systemic antineoplastic or radiation therapy within 14 days of cytotoxic agents within 21 days before the first dose of study treatment. Treatment with any investigational products within 21 days before the first dose of study treatment. Treatment with any investigational proteasome inhibitor. Systemic treatment with prohibited medication. Ongoing therapy with corticosteroids greater than 10mg of prednisone or its equivalent per day. Inhaled and topical steroids are permitted. Central nervous system involvement. Evidence of current uncontrolled cardiovascular conditions, including cardiac arrhythmias, congestive heart failure, angina, or myocardial infarction within the past 6 months. QTc &gt; 470 milliseconds on a 12lead ECG obtained during the screening period. Known human immunodeficiency virus (HIV) positive, hepatitis B surface antigenpositive status, or known or suspected active hepatitis C infection. Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to the protocol. Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption of tolerance of IXAZOMIB including difficulty swallowing.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Relapsed multiple myeloma</keyword>
	<keyword>Refractory multiple myeloma</keyword>
	<keyword>IXAZOMIB Proteasome inhibitor</keyword>
</DOC>